Integra LifeSciences Holdings Corp. (NASDAQ:IART) has earned a consensus rating of “Buy” from the ten analysts that are presently covering the company. Three equities research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $83.67.

IART has been the topic of a number of recent analyst reports. Barclays PLC boosted their price target on shares of Integra LifeSciences Holdings Corp. from $77.00 to $84.00 and gave the stock an “equal weight” rating in a research note on Friday, July 29th. Zacks Investment Research lowered shares of Integra LifeSciences Holdings Corp. from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. Piper Jaffray Cos. reiterated an “overweight” rating and set a $85.00 price target on shares of Integra LifeSciences Holdings Corp. in a research note on Friday, June 24th. JPMorgan Chase & Co. initiated coverage on shares of Integra LifeSciences Holdings Corp. in a research note on Wednesday, July 13th. They set an “overweight” rating on the stock. Finally, Jefferies Group boosted their price target on shares of Integra LifeSciences Holdings Corp. from $81.00 to $95.00 and gave the stock a “buy” rating in a research note on Friday, July 29th.

Shares of Integra LifeSciences Holdings Corp. (NASDAQ:IART) traded up 0.51% on Wednesday, reaching $87.07. The company’s stock had a trading volume of 106,794 shares. The firm has a market capitalization of $3.25 billion, a PE ratio of 359.79 and a beta of 0.52. The firm has a 50-day moving average price of $85.44 and a 200 day moving average price of $75.74. Integra LifeSciences Holdings Corp. has a one year low of $54.75 and a one year high of $88.86.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/integra-lifesciences-holdings-corp-nasdaqiart-given-average-rating-of-buy-by-analysts.html

Integra LifeSciences Holdings Corp. (NASDAQ:IART) last announced its earnings results on Thursday, July 28th. The company reported $0.79 EPS for the quarter, beating analysts’ consensus estimates of $0.76 by $0.03. Integra LifeSciences Holdings Corp. had a net margin of 0.79% and a return on equity of 15.41%. The business earned $249.30 million during the quarter, compared to analysts’ expectations of $243.17 million. During the same period in the prior year, the company earned $0.79 earnings per share. The business’s revenue was up 17.2% compared to the same quarter last year. On average, analysts anticipate that Integra LifeSciences Holdings Corp. will post $3.48 earnings per share for the current fiscal year.

In other news, Director Raymond G. Murphy sold 2,610 shares of the stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $84.83, for a total value of $221,406.30. Following the sale, the director now directly owns 33,057 shares in the company, valued at $2,804,225.31. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Richard D. Gorelick sold 4,000 shares of the stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $84.60, for a total transaction of $338,400.00. Following the completion of the sale, the vice president now owns 9,702 shares in the company, valued at $820,789.20. The disclosure for this sale can be found here. 22.00% of the stock is currently owned by insiders.

Hedge funds have recently added to or reduced their stakes in the stock. Suntrust Banks Inc. raised its stake in Integra LifeSciences Holdings Corp. by 0.4% in the second quarter. Suntrust Banks Inc. now owns 4,758 shares of the company’s stock valued at $379,000 after buying an additional 20 shares in the last quarter. Miles Capital Inc. increased its position in shares of Integra LifeSciences Holdings Corp. by 1.5% in the second quarter. Miles Capital Inc. now owns 4,257 shares of the company’s stock valued at $340,000 after buying an additional 63 shares during the last quarter. Louisiana State Employees Retirement System increased its position in shares of Integra LifeSciences Holdings Corp. by 0.8% in the second quarter. Louisiana State Employees Retirement System now owns 12,900 shares of the company’s stock valued at $1,029,000 after buying an additional 100 shares during the last quarter. PineBridge Investments L.P. increased its position in shares of Integra LifeSciences Holdings Corp. by 4.4% in the second quarter. PineBridge Investments L.P. now owns 3,681 shares of the company’s stock valued at $293,000 after buying an additional 154 shares during the last quarter. Finally, Burney Co. increased its position in shares of Integra LifeSciences Holdings Corp. by 5.9% in the second quarter. Burney Co. now owns 3,385 shares of the company’s stock valued at $270,000 after buying an additional 190 shares during the last quarter. Institutional investors and hedge funds own 88.32% of the company’s stock.

About Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties.

5 Day Chart for NASDAQ:IART

Receive News & Ratings for Integra LifeSciences Holdings Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corp. and related companies with MarketBeat.com's FREE daily email newsletter.